These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28222634)

  • 61. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
    Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
    J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PREVENTION OF HEART FAILURE PATIENTS WITH DECREASED EJECTION FRACTION IN NON-CARDIAC SURGERY: LEVOSIMENDAN OR ANESTHETIC CARDIOPROTECTION?
    Likhvantsev VV; Marchenko DN; Grebenshchikov OA; Ubasev YV; Zabelina TS; Timoshin SS; Skripkin YV; Ovezov AM; Lar'kov RN; Philippovskaya ZS; Sungurov VA
    Anesteziol Reanimatol; 2016 Nov; 61(6):411-417. PubMed ID: 29894607
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improvement in Doppler alternans in patients with severe heart failure: Levosimendan versus dobutamin.
    Yilmaz MB; Karadas F; Erdem A; Tandogan I
    Int J Cardiol; 2008 Mar; 125(1):104-6. PubMed ID: 17428556
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
    Lechner E; Moosbauer W; Pinter M; Mair R; Tulzer G
    Pediatr Crit Care Med; 2007 Jan; 8(1):61-3. PubMed ID: 17149153
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
    Pölzl G; Altenberger J; Baholli L; Beltrán P; Borbély A; Comin-Colet J; Delgado JF; Fedele F; Fontana A; Fruhwald F; Giamouzis G; Giannakoulas G; Garcia-González MJ; Gustafsson F; Kaikkonen K; Kivikko M; Kubica J; von Lewinski D; Löfman I; Malfatto G; Manito N; Martínez-Sellés M; Masip J; Merkely B; Morandi F; Mølgaard H; Oliva F; Pantev E; Papp Z; Perna GP; Pfister R; Piazza V; Bover R; Rangel-Sousa D; Recio-Mayoral A; Reinecke A; Rieth A; Sarapohja T; Schmidt G; Seidel M; Störk S; Vrtovec B; Wikström G; Yerly P; Pollesello P
    Int J Cardiol; 2017 Sep; 243():389-395. PubMed ID: 28571618
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study).
    Altenberger J; Parissis JT; Ulmer H; Poelzl G;
    Eur J Heart Fail; 2010 Feb; 12(2):186-92. PubMed ID: 20083626
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy.
    Labbene I; Arrigo M; Tavares M; Hajjej Z; Brandão JL; Tolppanen H; Feliot E; Gayat E; Ferjani M; Mebazaa A
    Anaesth Crit Care Pain Med; 2017 Feb; 36(1):39-42. PubMed ID: 27436451
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
    Silvetti S; Greco T; Di Prima AL; Mucchetti M; de Lurdes CM; Pasin L; Scandroglio M; Landoni G; Zangrillo A
    Clin Res Cardiol; 2014 Jul; 103(7):505-13. PubMed ID: 24368740
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
    Lunghetti S; Palmerini E; Urselli R; Maffei S; Guarino E; Focardi M; Mondillo S; Favilli R
    Cardiol J; 2011; 18(5):532-7. PubMed ID: 21947989
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure.
    Yilmaz MB; Yontar C; Erdem A; Karadas F; Yalta K; Turgut OO; Yilmaz A; Tandogan I
    Heart Vessels; 2009 Jan; 24(1):16-21. PubMed ID: 19165563
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
    Kurt IH; Yavuzer K; Batur MK
    Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report].
    Biegus J; Zymliński R; Kulej K; Szachniewicz J; Banasiak W; Jankowska EA; Ponikowski P
    Kardiol Pol; 2013; 71(3):275-8. PubMed ID: 23575784
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic value of noninvasive hemodynamic evaluation of the acute effect of levosimendan in advanced heart failure.
    Malfatto G; Della Rosa F; Rella V; Villani A; Branzi G; Blengino S; Giglio A; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2014 Apr; 15(4):322-30. PubMed ID: 24699010
    [TBL] [Abstract][Full Text] [Related]  

  • 77. First experiences with intraoperative Levosimendan in pediatric cardiac surgery.
    Osthaus WA; Boethig D; Winterhalter M; Huber D; Goerler H; Sasse M; Sümpelmann R
    Eur J Pediatr; 2009 Jun; 168(6):735-40. PubMed ID: 18813947
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
    de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
    Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion.
    Tarkia M; Stark C; Haavisto M; Kentala R; Vähäsilta T; Savunen T; Strandberg M; Saunavaara V; Tolvanen T; Teräs M; Pietilä M; Nyman L; Duvall E; Saukko P; Levijoki J; Roivainen A; Saraste A; Knuuti J
    Heart; 2016 Mar; 102(6):465-71. PubMed ID: 26762238
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.